Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway

被引:2
|
作者
Nakanishi, T
Hayashi, A
Kunisawa, J
Tsutsumi, Y
Tanaka, K
Yashiro-Ohtani, Y
Nakanishi, M
Fujiwara, H
Hamaoka, T
Mayumi, T
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Toxicol, Osaka, Japan
[3] Osaka Univ, Sch Med, Biomed Res Ctr, Osaka 553, Japan
[4] Osaka Univ, Res Inst Microbial Dis, Osaka, Japan
关键词
cytotoxic T lymphocyte; MHC class I; fusogenic liposome; vaccine; ovalbumin;
D O I
10.1002/1521-4141(200006)30:6<1740::AID-IMMU1740>3.0.CO;2-U
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Exogenous soluble proteins enter the endosomal pathway by endocytosis and are presented in association with MHC class II rather than class I. In contrast, the delivery of exogenous protein antigens (Ag) into the cytosol generates MHC class I-restricted cytotoxic T lymphocytes (CTL) responses. Although several immunization approaches, such as the utilization of liposomes, have induced the in vivo priming of MHC class I-restricted CTL responses to protein Ag, it remains unclear whether this priming results from the direct delivery of protein Ag to the cytosol. Here we report that fusogenic liposomes (FL), which are prepared by fusing simple liposomes with Sendai virus particles, can deliver the encapsulated soluble protein directly into the cytosol of cells cultured concurrently and introduce it into the conventional MHC class I Ag presentation pathway. Moreover, a single immunization with ovalbumin (OVA) encapsulated in FL but not in simple liposomes results in the potent priming of OVA-specific CTL. Thus, FL function as an efficient tool for the delivery of CTL vaccines.
引用
收藏
页码:1740 / 1747
页数:8
相关论文
共 50 条
  • [41] De-N-glycosylation will be the novel pathway for processing of the tumor antigen presented by MHC class I
    Kondo, A
    TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, 1996, 8 (42) : 299 - 300
  • [42] Hepatocytes express abundant surface class I MHC and efficiently use transporter associated with antigen processing, tapasin, and low molecular weight polypeptide proteasome subunit components of antigen processing and presentation pathway
    Chen, M
    Tabaczewski, P
    Truscott, SM
    Van Kaer, L
    Stroynowski, I
    JOURNAL OF IMMUNOLOGY, 2005, 175 (02): : 1047 - 1055
  • [43] ANTIGEN-PROCESSING BY THE CLASS-I PATHWAY
    BENHAM, AM
    NEEFJES, JJ
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (03) : 664 - 669
  • [44] Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells
    Voeten, JTM
    Rimmelzwaan, GF
    Nieuwkoop, NJ
    Fouchier, RAM
    Osterhaus, ADME
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2001, 125 (03): : 423 - 431
  • [45] Characterisation of the interaction sites between MHC class I and TAPBPR, a new component of the MHC class I processing pathway
    Hermann, C.
    Strittmatter, L. M.
    Prankerd-Smith, C. A. O.
    Burr, M. L.
    Boyle, L. H.
    IMMUNOLOGY, 2012, 137 : 18 - 18
  • [46] The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation
    Oh, YK
    Harding, CV
    Swanson, JA
    VACCINE, 1997, 15 (05) : 511 - 518
  • [47] Emerging roles of immunoproteasomes beyond MHC class I antigen processing
    Frédéric Ebstein
    Peter-Michael Kloetzel
    Elke Krüger
    Ulrike Seifert
    Cellular and Molecular Life Sciences, 2012, 69 : 2543 - 2558
  • [48] Viral evasion of the MHC class I antigen-processing machinery
    Sandra Loch
    Robert Tampé
    Pflügers Archiv, 2005, 451 : 409 - 417
  • [49] Molecular aspects of MHC class I-restricted antigen processing
    Cresswell, P.
    IMMUNOLOGY, 2013, 140 : 7 - 7
  • [50] CTL TARGETING OF TUMORS WITH DEFECTS IN MHC CLASS I ANTIGEN PROCESSING
    Wolpert, Elisabeth Z.
    van Hall, Thorbald
    Grufman, Per
    van der Veer, Michael
    Laban, Sandra
    Fredriksson, Vanoohi
    Camps, Marcel
    Torstensson, Elisabeth
    Ossendorp, Ferry
    Ljunggren, Hans-Gustaf
    Kaerrel, Klas
    Melief, Cornelis J. M.
    Offringa, Rienk
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3672 - 3672